ennifer R. Brown, MD, PhD, the Worthington and Margaret Collette Professor of Medicine in the Field of Hematologic Oncology at Harvard Medical School and Dana-Farber Cancer and study chair of this trial Institute (IMAGE)
Caption
For decades, people diagnosed with CLL or SLL have often faced the reality of long-term or even lifelong cancer treatments, as these slow-growing cancers tend to recur frequently, requiring additional maintenance therapies. Despite high survival rates (about 94% of patients live five years after diagnosis), the burden of ongoing therapy can deeply affect the lives of patients and their families. That’s where this new study hopes to make a difference. The study aims to find out whether these two targeted cancer pills can work together to control CLL/SLL so effectively that some patients may be able to stop treatment earlier, based on how their disease responds.
“Because CLL and SLL are such slow-growing but treatable cancers, many patients must undergo regular treatments for years to keep their cancer at bay,” said Jennifer R. Brown, MD, PhD, the Worthington and Margaret Collette Professor of Medicine in the Field of Hematologic Oncology at Harvard Medical School, Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute, and study chair of this trial. “If successful, this new treatment plan could prove to be life-changing for these individuals. The ability to dramatically reduce the number of ongoing appointments, treatments, side effects and co-pays would give patients and their families much more freedom to enjoy their lives, despite a diagnosis of cancer.”
Credit
Dana-Farber Cancer Institute
Usage Restrictions
none
License
Original content